Valued at USD 18.82 billion in 2025, the prostate cancer treatment market is projected to reach USD 20.83 billion in 2026 and USD 47.78 billion by 2034, growing at a CAGR of 10.9% during the forecast period 2026–2034. Active participants include AbbVie Inc., Accord Healthcare, Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Bayer AG, Dendreon Pharmaceuticals LLC, Ferring Pharmaceuticals, Ipsen Pharma, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., Sanofi, Takeda Pharmaceutical Company Ltd., and Tolmar Pharmaceuticals, Inc. Growth is propelled by the rising prevalence of prostate cancer, government initiatives to spread awareness, and rising investments from government and private entities in innovative screening and diagnostic methods. The market covers hormonal therapy, chemotherapy, radiation therapy, cancer immunotherapy, and advanced options such as targeted therapies and radiopharmaceuticals.

Drug Class Segmentation in the Prostate Cancer Treatment Market

By drug class, the market is segmented into hormonal therapy, chemotherapy, immunotherapy, targeted therapy, and others. Hormonal therapy held the largest revenue share of 54.0% in 2025 owing to its widespread use as the first-line treatment, particularly in advanced and metastatic stages. Androgen deprivation therapies and androgen receptor inhibitors are key components of the segment, which benefits from established efficacy and a growing number of patients diagnosed at advanced stages. Drugs such as enzalutamide and abiraterone acetate are significant contributors, supported by broad adoption in clinical practice.

Targeted therapy is projected to register the highest growth among drug classes, at a CAGR of 14.10% during the forecast period. Advancements in precision medicine and increasing approvals of novel agents underpin this trajectory. The emergence of radiopharmaceuticals and PARP inhibitors has expanded options for patients with specific genetic mutations or metastatic conditions, and the FDA approval of Lynparza (olaparib) for BRCA-mutated metastatic prostate cancer underscores the growing importance of biomarker-driven personalization. Rising research and development activity is expected to sustain demand for this segment.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/prostate-cancer-treatment-market

Precision Medicine and Technology Advances

Precision medicine has gained prominence as health professionals increasingly rely on genomic information when making treatment decisions. Testing biomarkers and conducting genomic profiling help identify mutations that may affect how patients respond to specific therapies, allowing clinicians to determine which treatments work best. Continued progress in cancer genomics is expected to widen these applications. Enhanced imaging techniques have improved early detection and staging accuracy, while robotic-assisted surgeries and radiopharmaceuticals are becoming more accessible.

Artificial intelligence is also entering clinical workflows. AI tools guide targeted therapies such as transurethral ultrasound ablation, support robotic surgery precision, and integrate imaging, biomarkers, and pathology to reduce unnecessary biopsies. Combination regimens, including hormonal therapy paired with chemotherapy or immunotherapy, and minimally invasive procedures are further notable trends.

Regional Insights

North America held the largest share of 42.0% in 2025, driven by high disease prevalence, advanced healthcare infrastructure, and strong adoption of innovative therapies. According to the American Cancer Society, prostate cancer is the most common cancer among men in the US, with an estimated 288,300 new cases in 2023 alone. Favorable reimbursement policies and the presence of key market players reinforce the region's leadership.

Europe represented 27.0% of the market in 2025, supported by a growing elderly population and high awareness of screening, with Germany, the UK, and France leading the regional market. Asia Pacific is emerging as the fastest-growing region at a CAGR of 13.20%, fueled by healthcare investment, rising prevalence, and improved access to care in China, Japan, and India.

Industry Developments and Outlook

In June 2026, RadioMedix announced FDA approval of its generic Ga-68 PSMA-11 radiodiagnostic for prostate cancer, expanding its precision nuclear medicine portfolio. In April 2026, TOBY, Inc. received FDA Breakthrough Device Designation for its urine-based Multi-Cancer Early Detection test. The high cost of treatments remains a restraint. Looking ahead, hormonal therapy is expected to remain a prominent modality, while targeted drugs and radioligand therapies emerge as major opportunities in advanced and metastatic disease, reinforcing the strategic value of the prostate cancer treatment market for B2B stakeholders.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market